Glenmark gets USFDA nod for anti-hypertension tablets

NEW DELHI: Glenmark Pharmaceuticals today said its American subsidiary has received the final approval from the US Food and Drug Administration (FDA) for Moexipril Hydrochloride tablets used for treating hypertension.

The USFDA has granted the final approval for tablets to the company's group firm Glenmark Generics Inc, Glenmark Pharma said in a statement to the National Stock Exchange.

Tablets are generic version of Schwarz Pharma's Uniretic. "The product is currently available and will begin shipping immediately," Glenmark said.

The product is indicated for the treatment of patients suffering from hypertension. Total sales for this combination during the 12-month period ending December 2009 were USD 8 million, according to IMS Health.

The latest approval comes shortly after Glenmark got the final approval for Ropinirole Hydrochloride tablets, the generic version of GSK's Requip tablets.

Shares of Glenmark today settled the trade at Rs 241.75, down by 0.56 per cent on the NSE.